TipRanks

Notifications

Tag: JNJ

Total 622 Posts

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Healthequity (HQY) and Bluebird Bio (BLUE)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Johnson & Johnson (JNJResearch Report), Healthequity (HQYResearch Report) and Bluebird Bio (BLUEResearch Report).

Johnson & Johnson (JNJ)

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson yesterday and set a price target of $163.00. The company’s shares closed last Tuesday at $155.77.

According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of 11.4% and a 62.1% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, GE Healthcare Technologies Inc, and Bausch + Lomb Corporation.

Currently, the analyst consensus on Johnson & Johnson is a Moderate Buy with an average price target of $178.85.

See Insiders’ Hot Stocks on TipRanks >>

Healthequity (HQY)

In a report released yesterday, Stan Berenshteyn from Wells Fargo assigned a Buy rating to Healthequity, with a price target of $93.00. The company’s shares closed last Tuesday at $79.48, close to its 52-week high of $84.49.

According to TipRanks.com, Berenshteyn is a 3-star analyst with an average return of 2.6% and a 61.4% success rate. Berenshteyn covers the Healthcare sector, focusing on stocks such as Health Catalyst, GoodRx Holdings, and Veeva Systems.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Healthequity with a $98.63 average price target, a 24.1% upside from current levels. In a report issued on March 15, Robert W. Baird also maintained a Buy rating on the stock with a $97.00 price target.

Bluebird Bio (BLUE)

In a report released yesterday, Yanan Zhu from Wells Fargo assigned a Hold rating to Bluebird Bio, with a price target of $3.00. The company’s shares closed last Tuesday at $1.20, close to its 52-week low of $0.88.

According to TipRanks.com, Zhu is a 5-star analyst with an average return of 20.3% and a 47.6% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Crispr Therapeutics AG.

Currently, the analyst consensus on Bluebird Bio is a Hold with an average price target of $4.45, representing a 275.5% upside. In a report released yesterday, William Blair also reiterated a Hold rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on JNJ: